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Introduction. Mannose-binding lectin (MBL) activates complement system and has been suggested to play a role in vascular
complications in diabetics. Carotid intima-media thickness (cIMT) detects subclinical atherosclerosis.We evaluated the association
of MBL and IMT in diabetic patients.Methods. SerumMBL levels (ng/mL) and cIMT (mm) were measured in a total of 103 type 2
diabetic (T2DM) patients (mean age 49.7 ± 8.2 years) and in 98 healthy controls (mean age 48.66 ± 1.29 years). MBL was measured
by sandwich ELISA. cIMT was measured using B mode ultrasound enlarged images. Data were analyzed by one-way analysis of
variance (ANOVA), simple correlation analysis, multiple correlation analysis, and Student’s t-test. Results. There was no significant
difference in MBL level in T2DM versus controls. As expected, IMT was significantly higher in T2DM patients (0.672 ± 0.148)
than in controls (0.6026 ± 0.128) (𝑃 = 0.001). In T2DM, the lowest cIMT was seen in patients with normal MBL level (500–1000)
while cIMT continuously increased with both high MBL and absolute MBL deficiency states. This was especially significant in
high MBL (0.725 ± 0.148) versus normal MBL T2DM patients (0.601 ± 0.122) (𝑃 = 0.002). On the basis of backward stepwise
multiple regression analysis in T2DM group, the main predictors of IMT are age (𝑃 < 0.003), ApoA level (𝑃 = 0.023), and theMBL
(𝑃 = 0.036). Conclusions. Our results suggest a dual role of MBL as a risk factor for cIMT in T2DM. In addition, MBL may also be
used as a marker of macrovascular disease, as both low and high levels indicate the susceptibility for atherosclerosis in T2DM.
1. Introduction
1
Diabetes mellitus is the most prevalent and independent risk
factor for atherosclerosis/cardiovascular diseases (CVD) [1]
including coronary artery disease (CAD). CVD is the leading
cause of mortality in type 2 diabetics (T2DM) [1]. Several
inflammatory markers (fibrinogen, CRP, IL-18, and TNF-
alpha) have been associated with markers of asymptomatic
atherosclerosis in type 2 diabetics [2]. Mannose-binding
lectin (MBL) has been suggested to play a role in the
pathogenesis of CVD in diabetics [3, 4].2
3
4
MBL, an important member of innate immunity, acti-
vating the lectin pathway of complement, is a weak-acute
phase reactant [5] and its level increases only two- to threefold
temporarily in response to different stress factors [6]. 5
Previous studies analyzing the role of MBL in CVD have
demonstrated a proatherogenic as well as an antiatherogenic
role. Low MBL pheno- or genotype has been associated
with higher risk of atherosclerosis [7, 8], arterial thrombosis
[9], coronary artery disease [10, 11], bypass graft occlusion
[12], and carotid artery plaques [13]. However, high MBL
levels or normal genotypes have also been associated with
2 Journal of Diabetes Research
MBL concentration
Control DM2
M
BL
 co
nc
. (
ng
/m
L)
0
1000
2000
3000
4000
5000
6000
(a)
MBL concentration
Control DM2
M
BL
 co
nc
. (
ng
/m
L)
10
100
1000
(b)
Figure 1: Box andWhisker plots of Mannose-binding lectin (MBL)
distribution in type 2 diabetics and controls. The median (lower
and upper quartiles) levels for MBL in T2DM and controls were
819 ng/mL (321–1871) and 846 ng/mL (247–1969), respectively.There
was no significant difference between either group.
coronary artery disease [14] and restenosis after carotid
endarterectomy [15]. Furthermore, in type 2 diabetic pop-
ulation, low MBL genotype is associated with increased
risk of cardiovascular events [16] and poorer outcomes of
myocardial infarction [17]. Whereas high MBL is associ-
ated with increased mortality [18], disease progression, and
nephropathy [19], protective role of highMBL in diabetics has
also been suggested [20].6
7
B mode ultrasonography mediated measurement of
8
carotid artery intima-media thickness (cIMT) permits the
study of subclinical carotid atherosclerosis, and patients at
high risk for CVD can be identified [21]. Studies assessing
correlation of MBL pheno- or genotypes with carotid intima-
media thickness [22, 23] are conflicting. Independent of tra-
ditional risk factors, a quadratic U-shaped relation between
serum MBL and cIMT was demonstrated in patients with
rheumatoid arthritis. It supported a notion; both high and
low MBL may play a role in CVD [24].
Table 1: Anthropometric and laboratory data of type 2 diabetics
(T2DM) and control group of our study population.
Parameter T2DM group Control group Significance
𝑛 = 103 𝑛 = 98
Age (year) 49.78 ± 0.81 48.66 ± 1.29 P = 0.929
Duration of diabetes
(years) 8.64 ± 0.62
Gender (M/F) 65/38 52/46 P = 0.151
BMI (kg/m2) 31.68 ± 0.51 29.67 ± 1.0 P = 0.299
Waist circumference
(cm) 110.74 ± 1.33 104.2 ± 2.6 P = 0.028
Smoking (Y/N) 22/81 23/75 P = 0.423
Hypertension (Y/N) 62/41 30/68 P < 0.001
Glucose (mmol/L) 10.17 ± 0.43 5.3 ± 0.13 P < 0.001
HbA1C (%) 8.18 ± 0.17 5.59 ± 0.07 P < 0.001
CRP (mg/L) 5.8 ± 1.08 5.63 ± 0.9 P = 0.98
Triglyceride
(mmol/L) 2.87 ± 0.29 1.53 ± 0.11 P = 0.001
Cholesterol (mmol/L) 5.03 ± 0.13 5.37 ± 0.11 P = 0.045
HDL-cholesterol
(mmol/L) 1.19 ± 0.03 2.29 ± 0.1 P < 0.001
LDL-cholesterol
(mmol/L) 2.91 ± 0.09 2.28 ± 0.12 P < 0.001
ApoA (g/L) 1.41 ± 0.03 1.56 ± 0.03 P = 0.001
ApoB100 (g/L) 0.91 ± 0.03 0.96 ± 0.03 P = 0.214
Lp(a) (mg/L) 344.9 ± 50 299.1 ± 39.1 P = 0.704
Table 2: Results of backward stepwise multiple regression analysis
with beta coefficient and significance. Age, ApoA, and MBL were
significantly associated with carotid intima-media thickness.
Parameter Beta coefficient Significance
Age (year) 0.400 P = 0.003
ApoA (g/L) −0.627 P = 0.023
MBL 0.272 P = 0.036
Cholesterol (mmol/L) 0.253 P = 0.074
HDL-cholesterol (mmol/L) 0.492 P = 0.055
ApoB100 (g/L) 0.021 P = 0.952
BMI 0.096 P = 0.537
ApoB100/ApoA 0.135 P = 0.68
Triglyceride (mmol/L) 0.035 P = 0.841
LDL-cholesterol (mmol/L) 0.107 P = 0.647
The objective of this study was to investigate hypothetical
dual role of serum MBL level in intima-media thickness
development among type 2 diabetic patients.
2. Methods
2.1. Study Design. After obtaining an institutional ethical
clearance and an informed consent from participants, type
2 diabetic patients (T2DM) attending diabetes outpatient
clinic at the Department of Internal Medicine, University of
Debrecen, were recruited for the study. Amongst the diabetic
Journal of Diabetes Research 3
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Figure 2: Box and Whisker plots depicting MBL distribution according to various subgroups in type 2 diabetics and control group.
Absolute MBL deficiency (<100 ng/mL), intermediate MBL deficiency (100–500 ng/mL), normal MBL (500–1000 ng/mL), and high MBL
levels (>1000 ng/mL) subgroups are depicted.
patients, patients with severe hypoglycemia, hyperglycemia,
diabetic ketoacidosis within three months prior to sample
collection, active infections, malignancy, and other comorbid
illnesses were excluded. We excluded pregnant females from
our study. Only Caucasians aged greater than/equal to 24
and less than/equal to 78 years were included. Healthy age-
matched subjects without diabetes were recruited as controls.
Subjects with smoking pack years ≥ 20 were considered as
smokers. Criteria for hypertension included patients with
three consecutive arterial blood pressure values equal to or
exceeding 140/90mmHg or use of antihypertensive med-
ication. Hypertensives (cases and controls) were included
only if they were well treated and did not have hypertensive
crisis within three months prior to sample collection. Of the
subjects who met our inclusion criteria, a total 103 T2DM
patients and 98 controls matched for age were involved
in the study. An informed consent, detailed history and
sociodemographic details, were obtained from all partici-
pants. Laboratory analysis and measurement of IMT was
carried out by personnel blinded to clinical status of the
subjects. 9
2.2. Laboratory Analysis. The blood samples were taken after
overnight fasting of at least 10 hours by qualified staff. Fresh
serum samples were used to analyze serum glucose, HbA1c,
and lipid profile using standard methods at the Department
of Laboratory Medicine, University of Debrecen. High sen-
sitivity C-reactive protein (CRP) was measured using Integra
700AutoAnalyzer system (Roche, Basel, Switzerland). Serum
samples were stored at −80∘ Celsius, for further analysis of
4 Journal of Diabetes Research
Carotid IMT
Control DM2
Ca
ro
tid
 IM
T 
(m
m
)
0.0
0.2
0.4
0.6
0.8
∗
∗
P = 0.005
Figure 3: Carotid intima-media thickness (IMT) (mm) in type
2 diabetic patients and controls. IMT was significantly higher in
T2DM patients (0.672 ± 0.148) than in controls (0.6026 ± 0.128)
(𝑃 = 0.001).
MBL levels.These samples were defrosted just before analysis
of MBL.10
2.3. MBL Levels. MBL concentrations were measured by
sandwich enzyme-linked immunosorbent assay as described
and used previously at our institution [25]. In short, murine
monoclonal antibody (Statens Serum Institut, Denmark),
which preferentially detects functional MBL oligomers, was
used. Microtiter plates (flat bottom, high binding capacity,
Greiner Bio-One, Mosonmagyarovar, Hungary) were coated
with primary antibody (HYB131-01) at 10 𝜇L/10mL, that is,
1/1000 dilution in Tris-buffered solution (TBS), and were
incubated overnight at 4∘ Celsius. Sera diluted 5-fold, 25-
fold, and 125-fold in dilution buffer and serial twofold
dilutions of an MBL serum standard (BioPorto Diagnostics
A/S) were added to the wells and incubated at 37∘ Celsius
for 90 minutes in a wet chamber. Biotin-labeled secondary
(HYB131-01B) antibody at 1.25 𝜇L/10mL (1/8000 dilution) in
TBS, 0.05% Tween-20, and 0.25𝜇M EDTA (TBS-T-EDTA)
was incubated at room temperature for 90 minutes in a wet
chamber. Horseradish peroxidase-conjugated biotin-avidin
complex (Vectastain, Vector Laboratories Inc., Burlingame,
CA) and substrate solution containing tetramethylbenzidine
dihydrochloride (TMB, Sigma Aldrich, Schnelldorf, Ger-
many) were used for obtaining color reaction. Reaction
was stopped with 2M H
2
SO
4
. Absorbance was measured
at 450 nm using an ELISA reader Infinity 200M (Tecan
Austria GmbH, Gro¨dig Austria). MBL concentration was
estimated by reference to the serum standard. The results
were calculated by the Magellan software program of the
ELISA reader, using Marquardt curve fitting.
2.4. Carotid Intima-Media Thickness (cIMT) Measurement.
PhilipsHD 11 XE ultrasound equipmentwith a 7.5MHz linear
transducer was used to measure IMT (mm). Online mea-
surements of IMT were performed in the far artery wall of
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Figure 4: Carotid intima-media thickness (IMT) (mm) in various
MBL subgroups in diabetics and controls. Amongst the controls,
there was no significant difference in IMT in the four MBL sub-
groups. In diabetics, lowest IMT was seen in subgroup with normal
MBL level (500–1000 ng/mL) while IMT continuously increased
with both high MBL and absolute MBL deficiency.
the common carotid arteries, 10mm proximal to the carotid
bulb [21]. All measurements were performed on frozen,
enlarged images at end-diastole, and the transducer was in
the mediolateral direction. IMT was measured on a 1 cm
segment. In each of these 1 cm segments, 10 measurements of
Journal of Diabetes Research 5
IMT were performed at 1-mm increments on both sides. The
mean IMT of the 20 values in each patient was calculated.
2.5. Statistical Analysis. All the statistical calculations were
performed using IBM SPSS Statistics 20.0 program pack-
age. MBL, serum triglyceride (Tg), HDL cholesterol, and
CRP showed a nonnormal distribution; hence, median and
interquartile ranges are used. All other values are given
as means ± standard deviation (SD). Spearman correla-
tion analysis was used to correlate IMT with MBL lev-
els in different groups of patients. Furthermore, because
both the MBL deficiency and the high MBL are associated
with elevated cardiovascular risk, each group (T2DM and
control) was subdivided according to serum MBL levels
into 4 subgroups: absolute MBL deficiency (<100 ng/mL),
intermediateMBL deficiency (100–500 ng/mL), normalMBL
(500–1000 ng/mL), and high MBL levels (>1000 ng/mL) to
analyze the possible nonlinear association between MBL
and IMT. IMT in different subgroups were compared using
one-way analysis of variance (ANOVA). We used binary
logistic regression with dichotomous categorization of cIMT
for high (>0.7) and low (<0.7) IMT groups. We also used
multiple linear regression analysis to evaluate themultivariate
associations between IMT (dependent variable) and CVD
risk factors (predictors).
3. Results
3.1. Baseline Characteristics and MBL. Baseline character-
istics of diabetics and controls are summarized in Table 1.
Both groups (T2DM and controls) were matched for age.
Moreover, they did not significantly differ in gender and
number of smokers. Although the number of patients with
hypertension in T2DM group was significantly higher but all
of them were well treated and had normal blood pressure.
The median (lower and upper quartiles) levels for MBL
in T2DM and controls were 819 ng/mL (321–1871) and 846
(247–1969), respectively. There was no significant difference
between either group (Figure 1). Through Spearman correla-
tion analysis,MBLwas not associatedwith age, gender, serum
glucose, HbA1c, hypertension, CRP, and total cholesterol
in both diabetic and control groups and with duration of
diabetes in the T2DM group.
Because of dual role of MBL in determination of CVD
risk, subgroups of subjects with absolute functional defi-
ciency (MBL < 100 ng/mL), intermediate deficiency (MBL
100–500 ng/mL), normal MBL (500–1000 ng/mL), and high
MBL level (>1000 ng/mL) within both DM2 and control
group were analyzed separately. The percentage of patients
among four MBL subgroups did not differ in T2DM and
control group, as seen in Figure 2. The IMT values of T2DM
and control patients in MBL subgroups are also depicted
in Figure 2. As expected, IMT was significantly higher in
T2DM patients (0.672 ± 0.148) than in controls (0.6026 ±
0.128) (𝑃 = 0.001) (Figure 3). Amongst the controls, there
was no significant difference in IMT in the four MBL
subgroups. Meanwhile, in T2DM, the lowest IMT was11
seen in subgroup with normal MBL level (500–1000 ng/mL)
while IMT continuously increased with both high MBL and
absoluteMBL deficiency states (Figure 4).This was especially
significant in high MBL T2DM group (0.725 ± 0.148) versus
normal MBL T2DM group (0.601 ± 0.122) (𝑃 = 0.002).
Similarly, in highMBL subgroup, IMT in T2DM patients was
higher than in controls (0.725 ± 0.148 and 0.58 ± 0.118, resp.,
𝑃 < 0.001) (Figure 4).
3.2. Correlation between MBL, IMT, and Clinical Parameters.
In the T2DM group, among patients with MBL levels above
500, there was a significant correlation between MBL level
and IMT (𝑟 = 0.379, 𝑃 = 0.001). Amongst the diabetics,
correlation of IMT and CVD risk factors showed strongest
associationwith age (𝑟 = 0.537), followed byMBL (𝑟 = 0.379)
and with duration of diabetes (𝑟 = 0.292). Moreover, ApoA
showed a negative correlation with IMT (𝑟 = −0.325, 𝑃 =
0.03). In controls, the male gender (𝑃 = 0.005), age (0.024),
BMI (0.005), waist circumference (𝑃 = 0.011), glucose (𝑃 =
0.009), and HbA1C (𝑃 = 0.017) were correlated significantly
with IMT.
3.3. Regression Analysis. Binary logistic regression analysis in
high IMT subgroup (>0.7) showed a significant contention
with ApoA (𝑃 = 0.03) and near significant values for age (𝑃 =
0.053), triglyceride (𝑃 = 0.053), and cholesterol (𝑃 = 0.056).
On the basis of backward stepwise multiple regression
analysis in T2DM group, the main predictors of IMT are
the age (𝑃 < 0.003), ApoA level (𝑃 = 0.023), and the
MBL (𝑃 = 0.036), while the total cholesterol level (𝑃 =
0.074) and HDL (𝑃 = 0.055) showed near significant
prediction. Other clinical factors (ApoB100, ApoB100/ApoA,
triglyceride, and LDL) were excluded. In control group, in
the backward stepwise multiple regression analysis the male
gender (𝑃 < 0.0001), the HDL level (𝑃 = 0.098), and
ApoB100/ApoA (𝑃 = 0.0001) were the predictors, while
other clinical parameters (cholesterol, HbA1C, ApoB100, TG,
glucose, CRP, BMI, waist circumference, MBL, LDL, and
ApoA) were excluded (Table 2).
4. Discussion
Our results show that IMT continuously increased with both
high MBL and absolute MBL deficiency states in T2DM
group.This study supports the hypothesis of dual association
between MBL levels and IMT in type 2 diabetic patients.
It shows for the first time that both high MBL levels and
absolute MBL deficiency states may contribute to increases
in cIMT in diabetics, as previously demonstrated, both
experimentally [26] and in patients with rheumatoid arthritis
[24].
MBL, an acute phase reactant, is synthesized by the
hepatocytes. On binding to specific carbohydrate molecules
it activates the complement through mannose associated
serine proteases [5, 27]. Although MBL concentration varies,
variations within an individual are very small compared
to the interindividual differences in a population [4]. In
Caucasians, the median concentration is 800–1,000 𝜇g/L
(ng/mL) [3]. We used a double monoclonal antibody assay,
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which is sensitive, and a reproducible method to determine
the MBL antigen levels in the sera. It accurately indicates the
function estimated by mannan-binding assay or complement
activation in the C4b deposition assay. Mutation homozy-
gotes or compound heterozygotes of MBL2 genotypes have
profoundly reduced MBL levels. However, due to additional
effects of noncoding polymorphisms and some unknown
factors, the individual MBL values vary substantially in wild-
type homozygotes and mutation heterozygotes, thereby only
providing a rough guide to serumMBL concentrations. Since
serum MBL levels vary markedly even amongst individuals
with identical genotypes, measuring MBL concentration in
serum is more reliable than genotyping [14, 20, 28].
Several mechanisms may underlie the atherogenic effect
of MBL deficiency. MBL has diverse functions like modula-
tion of inflammation, recognition of altered self-structures,
apoptotic cell clearance [29, 30], and removal of antigen-
antibody complexes [31, 32]. Thus, in a state of MBL defi-
ciency, apoptotic/damaged cells are not sequestered caus-
ing lipid accumulation and atherosclerosis. Furthermore,
variant alleles cause defective complement activation due
to decreased oligomerization and dysfunctional association
with ligands [33], thereby causing impaired clearance of large
triglyceride rich very low density lipoproteins (VLDL) [34,
35] and promoting atherosclerosis. Low MBL may lead to
enhanced proinflammatory cytokines, such as IL-6 [36] and
TNF-alpha [37] which are predictors of CVD.
Furthermore, MBL is an important component of innate
immunity. Thus, low MBL levels and variant alleles increase
infection susceptibility [31]. Acute infections in children
have been shown to derange lipid levels and increase IMT
[38]. Chronic infection may lead to increased production
of serum amyloid A and other acute phase proteins that
change the role of HDL from being anti-inflammatory to
a proinflammatory state [39]. Several studies have shown
an association between CVD and various infectious agents
including cytomegalovirus, Helicobacter pylori, and Chlamy-
dia pneumoniae (C. pneumoniae) [40]. C. pneumoniae infec-
tion provokes severe CAD in individuals with variant alleles
(low MBL) [41].
In heart ischemia reperfusion model, inhibition of lectin
pathway significantly decreases infarct size in type 2 dia-
betic rats [42], whereas MBL plays a critical role in type
1 diabetic mice [43]. Diabetes may cause advanced glyca-
tion end products of endothelial surfaces causing increased
MBL deposition with subsequent complement activation,
tissue injury, and atherosclerosis [44]. Terminal complement
deposits (C5b-9) were found in the intima of atherosclerotic
lesions [45]. Hyperglycemia mediates O-glycation of N-
acetylglucosamine (GlcNAc) [46] of various proteins includ-
ing LDL, membrane phospholipids, and apolipoprotein B
[44]. MBL strongly binds to these GlcNAc residues [47] caus-
ing increased susceptibility to oxidation and leads to func-
tional alterations in LDL clearance [31]. Moreover, glycation
causes inactivation of CD59, a regulatory protein involved
in decreasing endothelial susceptibility to membrane attack
complex mediated injury [48]. The above mechanisms could
act towards promoting atherosclerosis in T2D with high
serumMBL.
We hypothesize that this dual role of MBL with IMT
in T2DM can be explained in view of various functions of
MBL. Absolute MBL deficiency may promote atherogenesis
by enhancingVLDL, proinflammatory cytokines, and predis-
posing to chronic infections which alters functions of HDL.
It may also restrict clearing of early atherosclerotic lesions
due to dysfunctional MBL oligomerization. Furthermore,
combination of highMBL level and hyperglycemia associated
with advanced glycation products, fructosamine, altered LDL
clearance, and defective CD59 may increase atherosclerosis.
In conclusion, the data presented demonstrate for the
first time the potential dual role of MBL in pathologic
processes leading to atherosclerosis in diabetic patients. MBL
deficiency and excess MBL are a risk factor for subclinical
carotid artery atherosclerosis in T2DM. In addition to the
potential role ofMBL in the atherogenesis it may also be used
as a marker of macrovascular disease, as both low and high
levels may indicate the susceptibility for atherosclerosis in
T2DM. Early screening of patients may help distinguish high
risk group and guide prophylactic initiatives. MBL can be
assessed as a member of inherited nontraditional risk factors
influencing the development of atherosclerosis significantly
in diabetic patients.
However, the main limitation of this study is the low
number of patients and therefore further studies with larger
population size are required to ascertain the exact role ofMBL
in atherosclerosis.
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